Melanoma vaccines

Cancer Investigation

Volumn 20, Issue 7-8, 2002, Pages 1012-1026

  Perales, Miguel Angel ^a   Wolchok, Jedd D ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Clinical trials; Melanoma; Tumor; Vaccine

Indexed keywords

ALLOGENEIC CELL VACCINE; AUTOLOGOUS CELL VACCINE; CARBOHYDRATE VACCINE; CARMUSTINE; CISPLATIN; DACARBAZINE; DENDRITIC CELL VACCINE; DNA VACCINE; HEAT SHOCK PROTEIN VACCINE; MELACINE; MELANOMA VACCINE; PEPTIDE VACCINE; PURIFIED PROTEIN VACCINE; RECOMBINANT VIRUS VACCINE; TAMOXIFEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MELANOMA; PRIORITY JOURNAL; REVIEW; TUMOR CELL; TUMOR IMMUNITY;

ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; MELANOMA; SKIN NEOPLASMS;

EID: 0036419056     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-120005918     Document Type: Review

References (112)

1. Livingston, P.O.; Takeyama, H.; Pollack, M.S.; Houghton, A.N.; Albino, A.; Pinsky, C.M.; Oettgen, H.F.; Old, L.J. Serological responses of melanoma patients to vaccines derived from allogeneic cultured melanoma cells. Int. J. Cancer 1983, 31 (5), 567-575.
2. Gercovich, F.G.; Gutterman, J.U.; Mavligit, G.M.; Hersh, E.M. Active specific immunization in malignant melanoma. Med. Pediatr. Oncol. 1975, 1 (3), 277-287.
3. Slingluff, C.L.; Seigler, H.F. Immunotherapy for malignant melanoma with a tumor cell vaccine. Ann. Plast. Surg. 1992, 28 (1), 104-107.
4. Morton, D.L.; Foshag, L.J.; Nizze, J.A.; Gupta, R.K.; Famatiga, E.; Hoon, D.S.; Irie, R.F. Active specific immunotherapy in malignant melanoma. Semin. Surg. Oncol. 1989, 5 (6), 420-425.
5. Haigh, P.I.; Difronzo, L.A.; Gammon, G.; Morton, D.L. Vaccine therapy for patients with melanoma. Oncology (Huntingt) 1999, 13 (11), 1561-1574.
6. Chan, A.D.; Morton, D.L. Active Immunotherapy with allogeneic tumor cell vaccines: Present status. Semin. Oncol. 1998, 25 (6), 611-622.
7. Bystryn, J.C.; Henn, M.; Li, J.; Shroba, S. Identification of immunogenic human melanoma antigens in a polyvalent melanoma vaccine. Cancer Res. 1992, 52 (21), 5948-5953.
8. Bystryn, J.C. Immunogenicity and clinical activity of a polyvalent melanoma antigen vaccine prepared from shed antigens. Ann. NY Acad. Sci. 1993, 690 (1), 190-203.
9. Okamoto, T.; Irie, R.F.; Fujii, S.; Huang, S.K.; Nizze, J.A.; Morton, D.L.; Hoon, D.S. Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy. J. Investig. Dermatol. 1998, 111 (6), 1034-1039.
10. Huang, S.K.; Okamoto, T.; Morton, D.L.; Hoon, D.S. Antibody responses to melanoma/melanocyte auto-antigens in melanoma patients. J. Investig. Dermatol. 1998, 111 (4), 662-667.
11. Reynolds, S.R.; Celis, E.; Sette, A.; Oratz, R.; Shapiro, R.L.; Johnston, D.; Fotino, M.; Bystryn, J.C. HLA-independent heterogeneity of Cd8 + T cell responses to mage-3, melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients. J. Immunol. 1998, 161 (12), 6970-6976.
12. Morton, D.L.; Foshag, L.J.; Hoon, D.S.; Nizze, J.A.; Famatiga, E.; Wanek, L.A.; Chang, C.; Davtyan, D.G.; Gupta, R.K.; Elashoff, R.; Irie, R.F. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann. Surg. 1992, 216 (4), 463-482.
13. Bystryn, J.C. Clinical activity of a polyvalent melanoma antigen vaccine. Recent results. Cancer Res. 1995, 139 (3), 337-348.
14. Hsueh, E.C.; Gupta, R.K.; Qi, K.; Morton, D.L. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J. Clin. Oncol. 1998, 16 (9), 2913-2920.
15. Mitchell, M.S. Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin. Oncol. 1998, 25 (6), 623-635.
16. Osanto, S.; Schiphorst, P.P.; Weijl, N.I.; Dijkstra, N.; Van Wees, A.; Brouwenstein, N.; Vaessen, N.; Van Krieken, J.H.; Hermans, J.; Cleton, F.J.; Schrier, P.I. Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line. Hum. Gene Ther. 2000, 11 (5), 739-750.
17. Arienti, F.; Belli, F.; Napolitano, F.; Sule-Suso, J.; Mazzocchi, A.; Gallino, G.F.; Cattelan, A.; Santantonio, C.; Rivoltini, L.; Melani, C.; Colombo, M.P.; Cascinelli, N.; Maio, M.; Parmiani, G.; Sanantonio, C. Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells. Hum. Gene Ther. 1999, 10 (18), 2907-2916.
18. Wallack, M.K.; Sivanandham, M.; Balch, C.M.; Urist, M.M.; Bland, K.I.; Murray, D.; Robinson, W.A.; Flaherty, L.; Richards, J.M.; Bartolucci, A.A.; Rosen, L. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: The final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J. Am. Coll. Surg. 1998, 187 (1), 69-77.
19. Berd, D.; Murphy, G.; Maguire, H.C.; Mastrangelo, M.J. Immunization with haptenized, autologous tumor cells induces inflammation of human melanoma metastases. Cancer Res. 1991, 51 (10), 2731-2734.
20. Dranoff, G.; Jaffee, E.; Lazenby, A.; Golumbek, P.; Levitsky, H.; Brose, K.; Jackson, V.; Hamada, H.; Pardoll, D.; Mulligan, R.C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 1993, 90 (8), 3539-3543.
21. Soiffer, R.; Lynch, T.; Mihm, M.; Jung, K.; Rhuda, C.; Schmollinger, J.C.; Hodi, F.S.; Liebster, L.; Lam, P.; Mentzer, S.; Singer, S.; Tanabe, K.K.; Cosimi, A.B.; Duda, R.; Sober, A.; Bhan, A.; Daley, J.; Neuberg, D.; Parry, G.; Rokovich, J.; Richards, L.; Drayer, J.; Berns, A.; Clift, S.; Cohen, L.K.; Mulligan, R.C. Dranoff, G. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 1998, 95 (22), 13141-13146.
22. Ellem, K.A.; O'Rourke, M.G.; Johnson, G.R.; Parry, G.; Misko, I.S.; Schmidt, C.W.; Parsons, P.G.; Burrows, S.R.; Cross, S.; Fell, A.; Li, C.L.; Bell, J.R.; Dubois, P.J.; Moss, D.J.; Good, M.F.; Kelso, A.; Cohen, L.K.; Dranoff, G.; Mulligan, R.C. A case report: Immune responses and clinical course of the first human use of granulocyte/macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy. Cancer Immunol. Immunother. 1997, 44 (1), 10-20.
23. Dranoff, G.; Soiffer, R.; Lynch, T.; Mihm, M.; Jung, K.; Kolesar, K.; Liebster, L.; Lam, P.; Duda, R.; Mentzer, S.; Singer, S.; Tanabe, K.; Johnson, R.; Sober, A.; Bhan, A.; Clift, S.; Cohen, L.; Parry, G.; Rokovich, J.; Richards, L.; Drayer, J.; Berns, A.; Mulligan, R.C. A phase I study of vaccination with autologous, irradiated melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor. Hum. Gene Ther. 1997, 8 (1), 111-123.
24. Chang, A.E.; Li, Q.; Bishop, D.K.; Normolle, D.P.; Redman, B.D.; Nickoloff, B.J. Immunogenetic therapy of human melanoma utilizing autologous tumor cells transduced to secrete granulocyte-macrophage colony-stimulating factor. Hum. Gene Ther. 2000, 11 (6), 839-850.
25. Trefzer, U.; Weingart, G.; Chen, Y.; Herberth, G.; Adrian, K.; Winter, H.; Audring, H.; Guo, Y.; Sterry, W.; Walden, P. Hybrid cell vaccination for cancer immune therapy: First clinical trial with metastatic melanoma. Int. J. Cancer 2000, 85 (5), 618-626.
26. Przepiorka, D.; Srivastava, P.K. Heat shock protein-peptide complexes as immunotherapy for human cancer. Mol. Med. Today 1998, 4 (11), 478-484.
27. Srivastava, P.K.; Udono, H. Heat shock protein-peptide complexes in cancer immunotherapy. Curr. Opin. Immunol. 1994, 6 (5), 728-732.
28. Srivastava, P.K. Purification of heat shock protein-peptide complexes for use in vaccination against cancers and intracellular pathogens. Methods 1997, 12 (2), 165-171.
29. Blachere, N.E.; Srivastava, P.K. Heat shock protein-based cancer vaccines and related thoughts on immunogenicity of human tumors. Semin. Cancer Biol. 1995, 6 (6), 349-355.
30. Eton, O.; East, M.J.; Ross, M.I.; Savary, C.A.; Tomasovic, S.P.; Reitsma, D.; Hawkins, E.S.; Srivastava, P.K. Autologous Tumor-Derived Heat-Shock Protein Peptide Complex-96 in Patients with Metastatic Melanoma; American Association for Cancer Research: San Francisco, CA, 2000.
31. Old, L.J. Cancer immunology: The search for specificity - G. H. A. Clowes Memorial Lecture. Cancer Res. 1981, 41361-41375.
32. Wolfel, T.; Hauer, M.; Schneider, J.; Serrano, M.; Wolfel, C.; Klehmann-Hieb, E.; De Plaen, E.; Hankeln, T.; Meyer zum Buschenfelde, K.H.; Beach, D. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995, 269 (5228), 1281-1284.
33. Robbins, P.F.; El-Gamil, M.; Li, Y.F.; Kawakami, Y.; Loftus, D.; Appella, E.; Rosenberg, S.A. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med. 1996, 183 (3), 1185-1192.
34. Chiari, R.; Foury, F.; De Plaen, E.; Baurain, J.F.; Thonnard, J.; Coulie, P.G. Two antigens recognized by autologous cytolytic T lymphocytes on a melanoma result from a single point mutation in an essential housekeeping gene. Cancer Res. 1999, 59 (22), 5785-5792.
35. Coulie, P.G.; Lehmann, F.; Lethe, B.; Herman, J.; Lurquin, C.; Andrawiss, M.; Boon, T. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc. Natl. Acad. Sci. USA 1995, 92 (17), 7976-7980.
36. Lurquin, C.; Van Pel, A.; Mariame, B.; De Plaen, E.; Szikora, J.P.; Janssens, C.; Reddehase, M.J.; Lejeune, J.; Boon, T. Structure of the gene of tum- transplantation antigen P91A: The mutated exon encodes a peptide recognized with Ld by cytolytic T cells. Cell 1989, 58 (2), 293-303.
37. Pieper, R.; Christian, R.E.; Gonzales, M.I.; Nishimura, M.I.; Gupta, G.; Settlage, R.E.; Shabanowitz, J.; Rosenberg, S.A.; Hunt, D.F.; Topalian, S.L. Biochemical identification of a mutated human melanoma antigen recognized by Cd4(+) T cells. J. Exp. Med. 1999, 189 (5), 757-766.
38. Wang, R.F.; Wang, X.; Atwood, A.C.; Topalian, S.L.; Rosenberg, S.A. Cloning genes encoding MHC class II-restricted antigens: Mutated CDC27 as a tumor antigen. Science 1999, 284 (5418), 1351-1354.
39. Moreau-Aubry, A.; Le Guiner, S.; Labarriere, N.; Gesnel, M.C.; Jotereau, F.; Breathnach, R. A processed pseudogene codes for a new antigen recognized by a Cd8(+) T cell clone on melanoma. J. Exp. Med. 2000, 191 (9), 1617-1624.
40. Van Den Eynde, B.J.; Gaugler, B.; Probst-Kepper, M.; Michaux, L.; Devuyst, O.; Lorge, F.; Weynants, P.; Boon, T. A New antigen recognized by cytolytic T lymphocytes on a human kidney tumor results from reverse strand transcription [See Comments]. J. Exp. Med. 1999, 190 (12), 1793-1800.
41. van der Bruggen, P.; Traversari, C.; Chomez, P.; Lurquin, C.; De Plaen, E.; Van den Eynde, B.; Knuth, A.; Boon, T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991, 254 (5038), 1643-1647.
42. Chen, Y.T.; Scanlan, M.J.; Sahin, U.; Tureci, O.; Gure, A.O.; Tsang, S.; Williamson, B.; Stockert, E.; Pfreundschuh, M.; Old, L.J. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. USA 1997, 94 (5), 1914-1918.
43. Old, L.J.; Chen, Y.T. New paths in human cancer serology. J. Exp. Med. 1998, 187 (8), 1163-1167.
44. Jager, E.; Chen, Y.T.; Drijfhout, J.W.; Karbach, J.; Ringhoffer, M.; Jager, D.; Arand, M.; Wada, H.; Noguchi, Y.; Stockert, E.; Old, L.J.; Knuth, A. Simultaneous humoral and cellular immune response against cancer-testis antigen Ny-ESO-1: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med. 1998, 187 (2), 265-270.
45. Jager, E.; Maeurer, M.; Hohn, H.; Karbach, J.; Jager, D.; Zidianakis, Z.; Bakhshandeh-Bath, A.; Orth, J.; Neukirch, C.; Necker, A.; Reichert, T.E.; Knuth, A. Clonal expansion of melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides. Int. J. Cancer 2000, 86 (4), 538-547.
46. Boyse, E.A.; Old, L.J. Some aspects of normal and abnormal cell surface genetics. Ann. Rev. Genet. 1969, 3, 269-290.
47. Houghton, A.N.; Eisinger, M.; Albino, A.P.; Cairncross, J.G.; Old, L.J. Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J. Exp. Med. 1982, 156 (6), 1755-1766.
48. Vijayasaradhi, S.; Bouchard, B.; Houghton, A.N. The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product. J. Exp. Med. 1990, 171 (4), 1375-1380.
49. Brichard, V.; Van Pel, A.; Wolfel, T.; Wolfel, C.; De Plaen, E.; Lethe, B.; Coulie, P.; Boon, T. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 1993, 178 (2), 489-495.
50. Wang, R.-F.; Appella, E.; Kawakami, Y.; Kang, X.; Ronsenberg, S.A. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J. Exp. Med. 1996, 184, 2207-2216.
51. Livingston, P.; Wong, G.; Adluri, S.; Too, Y.; Padavan, M.; Parente, R.; Hanlon, C.; Calves, M.; Helling, F.; Ritter, G.; Oetten, H.; Old, L.J. Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside. J. Clin. Oncol. 1994, 12, 1036-1044.
52. Helling, F.; Zhang, S.; Shang, A.; Adluri, S.; Calves, M.; Koganty, R.; Longenecker, B.M.; Yao, T.J.; Oettgen, H.F.; Livingston, P.O. GM2-KLH conjugate vaccine: Increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res. 1995, 55 (13), 2783-2788.
53. Chapman, P.B.; Morrissey, D.M.; Panageas, K.S.; Hamilton, W.B.; Zhan, C.; Destro, A.N.; Williams, L.; Israel, R.J.; Livingston, P.O. Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin +QS21 vaccine: A dose-response study. Clin. Cancer Res. 2000, 6 (3), 874-879.
54. Kirkwood, J.M.; Ibrahim, J.G.; Sosman, J.A.; Sondak, V.K.; Agarwala, S.S.; Ernstoff, M.S.; Rao, U. High-dose interferon Alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801. J. Clin. Oncol. 2001, 19 (9), 2370-2380.
55. Chapman, P.B.; Morrissey, D.M.; Ibrahim, J.; Richards, T.; Lawson, D.; Israel, R.J.; Atkins, M.B.; Kirkwood, J.M. Eastern Cooperative Oncology Group Phase II Randomized Adjuvant Trial of GM2-KLH +QS21 (GMK) Vaccine +/- High Dose Interferon-Alpha2b (HD IFN) in Melanoma; American Society of Clinical Oncology: Atlanta, GA, 1999.
56. Hamilton, W.B.; Helling, F.; Lloyd, K.O.; Livingston, P.O. Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography. Int. J. Cancer 1993, 53 (4), 566-573.
57. Ritter, G.; Boosfeld, E.; Adluri, R.; Calves, M.; Oettgen, H.F.; Old, L.J.; Livingston, P. Antibody response to immunization with ganglioside gd3 and gd3 congeners (lactones, amide and gangliosidol) in patients with malignant melanoma. Int. J. Cancer 1991, 48 (3), 379-385.
58. Ragupathi, G.; Meyers, M.; Adluri, S.; Howard, L.; Musselli, C.; Livingston, P.O. Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21. Int. J. Cancer 2000, 85 (5), 659-666.
59. Cheung, N.K.; Canete, A.; Cheung, I.Y.; Ye, J.N.; Liu, C. Disialoganglioside GD2 anti-idiotypic monoclonal antibodies. Int. J. Cancer 1993, 54 (3), 499-505.
60. Saleh, M.N.; Stapleton, J.D.; Khazaeli, M.B.; LoBuglio, A.F. Generation of a human anti-idiotypic antibody that mimics the GD2 antigen. J. Immunol. 1993, 151 (6), 3390-3398.
61. Sen, G.; Chakraborty, M.; Foon, K.A.; Reisfeld, R.A.; Bhattacharya-Chatterjee, M. Preclinical evaluation in nonhuman primates of murine monoclonal anti-idiotype antibody that mimics the disialoganglioside GD2. Clin. Cancer Res. 1997, 3 (11), 1969-1976.
62. Foon, K.A.; Lutzky, J.; Baral, R,N.; Yannelli, J.R.; Hutchins, L.; Teitelbaum, A.; Kashala, O.L.; Das, R.; Garrison, J.; Reisfeld, R.A.; Bhattacharya-Chatterjee, M. Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. J. Clin. Oncol. 2000, 18 (2), 376-384.
63. Yao, T.J.; Meyers, M.; Livingston, P.O.; Houghton, A.N.; Chapman, P.B. Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies. Clin. Cancer Res. 1999, 5 (1), 77-81.
64. McCaffery, M.; Yao, T.J.; Williams, L.; Livingston, P.O.; Houghton, A.N.; Chapman, P.B. Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: Enhanced immunogenicity when combined with adjuvant. Clin. Cancer Res. 1996, 2 (4), 679-686.
65. Tai, T.; Paulson, J.C.; Cahan, L.D.; Irie, R.F. Ganglioside GM2 as a human tumor antigen (OFA-1-1). Proc. Natl. Acad. Sci. USA 1983, 80 (17), 5392-5396.
66. Grant, S.C.; Kris, M.G.; Houghton, A.N.; Chapman, P.B. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus bacillus calmette-guerin. Clin. Cancer Res. 1999, 5 (6), 1319-1323.
67. Chapman, P.B.; Morrissey, D.M.; Panageas, K.S.; Williams, L.; Lewis, J.J.; Israel, R.J.; Hamilton, W.B.; Livingston, P.O. Vaccination with a bivalent G(M2) and G(D2) ganglioside conjugate vaccine: A trial comparing doses of G(D2)-keyhole limpet hemocyanin. Clin. Cancer Res. 2000, 6 (12), 4658-4662.
68. Marchand, M.; van Baren, N.; Weynants, P.; Brichard, V.; Dreno, B.; Tessier, M.H.; Rankin, E.; Parmiani, G.; Arienti, F.; Humblet, Y.; Bourlond, A.; Vanwijck, R.; Lienard, D.; Beauduin, M.; Dietrich, P.Y.; Russo, V.; Kerger, J.; Masucci, G.; Jager, E.; De Greve, J.; Atzpodien, J.; Brasseur, F.; Coulie, P.G.; van der Bruggen, P.; Boon, T. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer 1999, 80 (2), 219-230.
69. Weber, J.S.; Hua, F.L.; Spears, L.; Marry, V.; Kuniyoshi, C.; Celis, E. A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma. J. Immunother. 1999, 22 (5), 431-440.
70. Lee, P.P.; Yee, C.; Savage, P.A.; Fong, L.; Brockstedt, D.; Weber, J.S.; Johnson, D.; Swetter, S.; Thompson, J.; Greenberg, P.D.; Roederer, M.; Davis, M.M. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 1999, 5 (6), 677-685.
71. Salgaller, M.L.; Marincola, F.M.; Cormier, J.N.; Rosenberg, S.A. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res. 1996, 56 (20), 4749-4757.
72. Jaeger, E.; Bernhard, H.; Romero, P.; Ringhoffer, M.; Arand, M.; Karbach, J.; Ilsemann, C.; Hagedorn, M.; Knuth, A. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: Implications for tumor vaccines with melanoma-associated antigens. Int. J. Cancer 1996, 66 (2), 162-169.
73. Rosenberg, S.A.; Yang, J.C.; Schwartzentruber, D.J.; Hwu, P.; Marincola, F.M.; Topalian, S.L.; Restifo, N.P.; Dudley, M.E.; Schwarz, S.L.; Spiess, P.J.; Wunderlich, J.R.; Parkhurst, M.R.; Kawakami, Y.; Seipp, C.A.; Einhorn, J.H.; White, D.E. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 1998, 4 (3), 321-327.
74. Wang, F.; Bade, E.; Kuniyoshi, C.; Spears, L.; Jeffery, G.; Marty, V.; Groshen, S.; Weber, J. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin. Cancer Res. 1999, 5 (10), 2756-2765.
75. Jager, E.; Ringhoffer, M.; Dienes, H.P.; Arand, M.; Karbach, J.; Jager, D.; Ilsemann, C.; Hagedorn, M.; Oesch, F.; Knuth, A. Granulocyte - Macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int. J. Cancer 1996, 67 (1), 54-62.
76. Zarour, H.M.; Kirkwood, J.M.; Kierstead, L.S.; Herr, W.; Brusic, V.; Slingluff, C.L.; Sidney, J.; Sette, A.; Storkus, W.J. Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive Cd4(+) T cells. Proc. Natl. Acad. Sci. USA 2000, 97 (1), 400-405.
77. Cormier, J.N.; Salgaller, M.L.; Prevette, T.; Barracchini, K.C.; Rivoltini, L.; Restifo, N.P.; Rosenberg, S.A.; Marincola, F.M. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J. Sci. Am. 1997, 3 (1), 37-44.
78. Lewis, J.J.; Janetzki, S.; Schaed, S.; Panageas, K.S.; Wang, S.; Williams, L.; Meyers, M.; Butterworth, L.; Livingston, P.O.; Chapman, P.B.; Houghton, A.N. Evaluation of CD8(+) T-cell frequencies by the elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide. Int. J. Cancer 2000, 87 (3), 391-398.
79. Scheibenbogen, C.; Schmittel, A.; Keilholz, U.; Allgauer, T.; Hofmann, U.; Max, R.; Thiel, E.; Schadendorf, D. Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. J. Immunother. 2000, 23 (2), 275-281.
80. Parkhurst, M.R.; Salgaller, M.L.; Southwood, S.; Robbins, P.F.; Sette, A.; Rosenberg, S.A.; Kawakami, Y. Improved Induction of Melanoma-Reactive CTL with Peptides from the Melanoma Antigen gp100 Modified at HLA-A*0201-Binding Residues. J. Immunol. 1996, 157 (6), 2539-2548.
81. Dyall, R.; Bowne, W.B.; Weber, L.W.; LeMaoult, J.; Szabo, P.; Moroi, Y.; Piskun, G.; Lewis, J.J.; Houghton, A.N.; Nikolic-Zugic, J. Heteroclitic immunization induces tumor immunity. J. Exp. Med. 1998, 188 (9), 1553-1561.
82. Slansky, E.J.; Rattis, M.F.; Boyd, F.L.; Fahmy, T.; Jaffee, M.E.; Schneck, P.J.; Margulies, H.D.; Pardoll, M.D. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. [In Process Citation]. Immunity 2000, 13 (4), 529-538.
83. Lee, K.H.; Wang, E.; Nielsen, M.B.; Wunderlich, J.; Migueles, S.; Connors, M.; Steinberg, S.M.; Rosenberg, S.A.; Marincola, F.M. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J. Immunol. 1999, 163 (11), 6292-6300.
84. Weeratna, R.D.; McCluskie, M.J.; Xu, Y.; Davis, H.L. CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine 2000, 18 (17), 1755-1762.
85. Schaed, S.G.; Houghton, A.N.; Klimek, V.M.; Butterworth, L.; Hwu, W.J.; Livingston, P.O.; Panageas, K.A.; Williams, L.; Dantis, L.; Lewis, J.J.; Chapman, P.B. Immunization of Melanoma Patients with Both Tyrosinase (370d) and gp100 (210m) Peptides: Comparison of Adjuvants and Peptide Immunogenicity; American Association for Cancer Research: San Francisco, CA, 2000.
86. Banchereau, J.; Steinman, R.M. Dendritic cells and the control of immunity. Nature 1998, 392 (6673), 245-252.
87. Dhodapkar, M.V.; Steinman, R.M.; Sapp, M.; Desai, H.; Fossella, C.; Krasovsky, J.; Donahoe, S.M.; Dunbar, P.R.; Cerundolo, V.; Nixon, D.F.; Bhardwaj, N. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J. Clin. Investig. 1999, 104 (2), 173-180.
88. Thurner, B.; Haendle, I.; Roder, C.; Dieckmann, D.; Keikavoussi, P.; Jonuleit, H.; Bender, A.; Maczek, C.; Schreiner, D.; von den Driesch, P.; Brocker, E.B.; Steinman, R.M.; Enk, A.; Kampgen, E.; Schuler, G. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 1999, 190 (11), 1669-1678.
89. Inaba, K.; Metlay, J.P.; Crowley, M.T.; Steinman, R.M. Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ. J. Exp. Med. 1990, 172 (2), 631-640.
90. Porgador, A.; Gilboa, E. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J. Exp. Med. 1995, 182 (1), 255-260.
91. Nestle, F.O.; Alijagic, S.; Gilliet, M.; Sun, Y.; Grabbe, S.; Dummer, R.; Burg, G.; Schadendorf, D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 1998, 4 (3), 328-332.
92. Mackensen, A.; Herbst, B.; Chen, J.L.; Kohler, G.; Noppen, C.; Herr, W.; Spagnoli, G.C.; Cerundolo, V.; Lindemann, A. Phase I Study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int. J. Cancer 2000, 86 (3), 385-392.
93. Schuler-Thurner, B.; Dieckmann, D.; Keikavoussi, P.; Bender, A.; Maczek, C.; Jonuleit, H.; Roder, C.; Haendle, I.; Leisgang, W.; Dunbar, R.; Cerundolo, V.; von Den Driesch, P.; Knop, J.; Brocker, E.B.; Enk, A.; Kampgen, E.; Schuler, G. Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1 + melanoma patients by mature monocyte-derived dendritic cells. J. Immunol. 2000, 165 (6), 3492-3496.
94. Kaplan, G.; Walsh, G.; Guido, L.S.; Meyn, P.; Burkhardt, R.A.; Abalos, R.M.; Barker, J.; Frindt, P.A.; Fajardo, T.T.; Celona, R. Novel responses of human skin to intradermal recombinant granulocyte/macrophage-colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing. J. Exp. Med. 1992, 175 (6), 1717-1728.
95. Nasi, M.L.; Lieberman, P.; Busam, K.J.; Prieto, V.; Panageas, K.S.; Lewis, J.J.; Houghton, A.N.; Chapman, P.B. Intradermal injection of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with metastatic melanoma recruits dendritic cells. Cytokines Cell. Mol. Ther. 1999, 5 (3), 139-144.
96. Bowne, W.B.; Wolchok, J.D.; Hawkins, W.G.; Srinivasan, R.; Gregor, P.; Blachere, N.E.; Moroi, Y.; Engelhorn, M.E.; Houghton, A.N.; Lewis, J.J. Injection of DNA encoding granulocyte-macrophage colony-stimulating factor recruits dendritic cells for immune adjuvant effects. Cytokines Cell. Mol. Ther. 1999, 5 (4), 217-225.
97. Overwijk, W.W.; Lee, D.S.; Surman, D.R.; Irvine, K.R.; Touloukian, C.E.; Chan, C.C.; Carroll, M.W.; Moss, B.; Rosenberg, S.A.; Restifo, N.P. Vaccination with a recombinant vaccinia virus encoding a "self' antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4(+) T lymphocytes. Proc. Natl. Acad. Sci. USA 1999, 96 (6), 2982-2987.
98. Bronte, V.; Apolloni, E.; Ronca, R.; Zamboni, P.; Overwijk, W.W.; Surman, D.R.; Restifo, N.P.; Zanovello, P. Genetic vaccination with "self' tyrosinase-related protein 2 causes melanoma eradication but not vitiligo. Cancer Res. 2000, 60 (2), 253-258.
99. Irvine, K.R.; Chamberlain, R.S.; Shulman, E.P.; Rosenberg, S.A.; Restifo, N.P. Route of immunization and the therapeutic impact of recombinant anticancer vaccines. J. Natl. Cancer Inst. 1997, 89 (5), 390-392.
100. Hirschowitz, E.A.; Leonard, S.; Song, W.; Ferris, B.; Leopold, P.L.; Lewis, J.J.; Bowne, W.B.; Wang, S.; Houghton, A.N.; Crystal, R.G. Adenovirus-mediated expression of melanoma antigen gp75 as immunotherapy for metastatic melanoma. Gene Ther. 1998, 5 (7), 975-983.
101. Rosenberg, S.A.; Zhai, Y.; Yang, J.C.; Schwartzentruber, D.J.; Hwu, P.; Marincola, F.M.; Topalian, S.L.; Restifo, N.P.; Seipp, C.A.; Einhorn, J.H.; Roberts, B.; White, D.E. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J. Natl. Cancer Inst. 1998, 90 (24), 1894-1900.
102. Porgador, A.; Irvine, K.R.; Iwasaki, A.; Barber, B.H.; Restifo, N.P.; Germain, R.N. Predominant role for directly transfected dendritic cells in antigen presentation to CD8 + T cells after gene gun immunization. J. Exp. Med. 1998, 188 (6), 1075-1082.
103. Casares, S.; Inaba, K.; Brumeanu, T.D.; Steinman, R.M.; Bona, C.A. Antigen presentation by dendritic cells after immunization with dna encoding a major histocompatibility complex class II-restricted viral epitope. J. Exp. Med. 1997, 186 (9), 1481-1486.
104. Akbari, O.; Panjwani, N.; Garcia, S.; Tascon, R.; Lowrie, D.; Stockinger, B. DNA vaccination: Transfection and activation of dendritic cells as key events for immunity. J. Exp. Med. 1999, 189 (1), 169-178.
105. Klinman, D.M.; Yi, A.K.; Beaucage, S.L.; Conover, J.; Krieg, A.M. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc. Natl. Acad. Sci. USA 1996, 93 (7), 2879-2883.
106. Sato, Y.; Roman, M.; Tighe, H.; Lee, D.; Corr, M.; Nguyen, M.D.; Silverman, G.J.; Lotz, M.; Carson, D.A.; Raz, E. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 1996, 273 (5273), 352-354.
107. Weber, L.W.; Bowne, W.B.; Wolchok, J.D.; Srinivasan, R.; Qin, J.; Moroi, Y.; Clynes, R.; Song, P.; Lewis, J.J.; Houghton, A.N. Tumor immunity and autoimmunity induced by immunization with homologous DNA. J. Clin. Investig. 1998, 102 (6), 1258-1264.
108. Bowne, W.B.; Srinivasan, R.; Wolchok, J.D.; Hawkins, W.G.; Blachere, N.E.; Dyall, R.; Lewis, J.J.; Houghton, A.N. Coupling and uncoupling of tumor immunity and autoimmunity. J. Exp. Med. 1999, 190 (11), 1717-1722.
109. Hawkins, W.G.; Gold, J.S.; Dyall, R.; Wolchok, J.D.; Hoos, A.; Bowne, W.B.; Srinivasan, R.; Houghton, A.N.; Lewis, J.J. Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity. Surgery 2000, 128 (2), 273-280.
110. Wang, R.; Doolan, D.L.; Le, T.P.; Hedstrom, R.C.; Coonan, K.M.; Charoenvit, Y.; Jones, T.R.; Hobart, P.; Margalith, M.; Ng, J.; Weiss, W.R.; Sedegah, M.; de Taisne, C.; Norman, J.A.; Hoffman, S.L. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998, 282 (5388), 476-480.
111. Boyer, J.D.; Cohen, A.D.; Vogt, S.; Schumann, K.; Nath, B.; Ahn, L.; Lacy, K.; Bagarazzi, M.L.; Higgins, T.J.; Baine, Y.; Ciccarelli, R.B.; Ginsberg, R.S.; MacGregor, R.R.; Weiner, D.B. Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 Env/Rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines. J. Infect. Dis. 2000, 181 (2), 476-483.
112. Ugen, K.E.; Nyland, S.B.; Boyer, J.D.; Vidal, C.; Lera, L.; Rasheid, S.; Chattergoon, M.; Bagarazzi, M.L.; Ciccarelli, R.; Higgins, T.; Baine, Y.; Ginsberg, R.; Macgregor, R.R.; Weiner, D.B. DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans. Vaccine 1998, 16 (19), 1818-1821.